Voyager Therapeutics

Yahoo Finance • last year

12 Best Healthcare Stocks For the Long-Term

In this piece, we will take a look at the 12 best healthcare stocks for the long term. If you want to skip our overview of the healthcare industry, then you can take a look at 5 Best Healthcare Stocks For the Long-Term. The healthcare ind... Full story

Yahoo Finance • last year

Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results

- GLP toxicology studies initiated for VY-TAU01 anti-tau antibody for Alzheimer’s disease to enable anticipated 1H 2024 IND filing - - SOD1 ALS gene therapy program on track for development candidate selection by end of year – - Conferen... Full story

Yahoo Finance • last year

Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast

CAMBRIDGE, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report third quarter 2023... Full story

Yahoo Finance • last year

Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that Chief Executive Officer Al... Full story

Yahoo Finance • last year

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into employment agreements with thr... Full story

Yahoo Finance • last year

Voyager Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that management will participate... Full story

Yahoo Finance • last year

Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer

CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Jacquelyn Fah... Full story

Yahoo Finance • 2 years ago

Voyager Therapeutics Presents Robust, Multi-Species Results from Preclinical Studies of IV-Delivered, TRACER™-Generated Novel Capsids at the ASGCT 26th Annual Meeting

CAMBRIDGE, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, presented data today validating the ability of no... Full story

Yahoo Finance • 2 years ago

OMass Therapeutics Announces Appointment of New Board Chair and Series B Extension

PRESSRELEASE OMassTherapeuticsAnnouncesAppointmentofNewBoardChair andSeries B Extension Jim Geraghty joins as Independent Director and Chair, bringing US and international experience from Genzyme and as NED and chair of multiple listed... Full story

Yahoo Finance • 2 years ago

Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results

- Neurocrine Biosciences strategic collaboration and Novartis license option exercise demonstrate Voyager pipeline and platform value and strengthen balance sheet - - Alzheimer’s disease franchise advances: selected lead candidate for ant... Full story

Yahoo Finance • 2 years ago

Voyager Therapeutics Announces Appointment of George Scangos, Ph.D., to Board of Directors

CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of George Scangos... Full story

Yahoo Finance • 2 years ago

Voyager Therapeutics Announces First Quarter 2023 Conference Call and Webcast

CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report first quarter 2023... Full story

Yahoo Finance • 2 years ago

Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer’s Disease and GBA1 Gene Therapy Program for Parkinson’s Disease at the AD/PD™ Conference

CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today presented new data from its anti-tau anti... Full story

Yahoo Finance • 2 years ago

Q4 2022 Voyager Therapeutics Inc Earnings Call

Participants Alfred W. Sandrock; President, CEO & Director; Voyager Therapeutics, Inc. Allen Nunnally; Chief Business Officer; Voyager Therapeutics, Inc. Peter P. Pfreundschuh; CFO; Voyager Therapeutics, Inc. Todd Carter; Chief Science... Full story

Yahoo Finance • 2 years ago

Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results

- Transformational progress in 2022 marked by reprioritization of high-value neurology pipeline and validation of TRACER™ novel capsid platform through transactions with Pfizer and Novartis - - Partnering momentum continues into 2023 with... Full story

Yahoo Finance • 2 years ago

Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets

Options exercised on two targets; Voyager eligible to receive associated development, regulatory, and commercial milestones, plus tiered royalties With option exercise, potential to expand agreement to include capsids for up to two additi... Full story

Yahoo Finance • 2 years ago

Voyager Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report fourth quarter and... Full story

Yahoo Finance • 2 years ago

Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases

- Voyager to receive up-front consideration of $175 million including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potential commercial milestones, tiered royalties on net sales, progr... Full story

Yahoo Finance • 2 years ago

Voyager Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that CEO Alfred W. Sandrock, Jr.... Full story

Yahoo Finance • 2 years ago

Voyager Therapeutics Appoints Grace E. Colón, Ph.D., to its Board of Directors

CAMBRIDGE, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Grace E. Coló... Full story